| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOGENETICS |
From the Department of Pharmaceutics, University of Florida, Gainesville, Florida.
Interethnic variability in pharmacokinetics can cause unexpected outcomes such as therapeutic failure, adverse effects, and toxicity in subjects of different ethnic origin undergoing medical treatment. It is important to realize that both genetic and environmental factors can lead to these differences among ethnic groups. The International Conference on Harmonization (ICH) published a guidance to facilitate the registration of drugs among ICH regions (European Union, Japan, the United States) by recommending a framework for evaluating the impact of ethnic factors on a drug's effect, as well as its efficacy and safety at a particular dosage and dosage regimen. This review focuses on the pharmacokinetic differences between East Asians and Caucasians. Differences in metabolism between East Asians and Caucasians are common, especially in the activity of several phase I enzymes such as CYP2D6 and the CYP2C subfamily. Before drug therapy, identification of either the genotype and/or the phenotype for these enzymes may be of therapeutic value, particularly for drugs with a narrow therapeutic index. Furthermore, these differences are relevant for international drug approval when regulatory agencies must decide if they accept results from clinical trials performed in other parts of the world.
Key Words: Interethnic variability • East Asians • Caucasians
Address for reprints: Hartmut Derendorf, PhD, FCP, 100494, Department of Pharmaceutics, University of Florida, Gainesville, FL 32610.
This article has been cited by other articles:
|
|
 |
|
  B. W. Corn, I. D. Wexler, M. Suntharalingam, M. Inbar, and W. J. Curran Jr Globalization of the Radiation Therapy Oncology Group: Implementation of a Model for Service Expansion and Public Health Improvement J. Clin. Oncol., March 1, 2008; 26(7): 1160 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suzuki, F. Broeyer, A. Cohen, M. Takebe, J. Burggraaf, and Y. Mizushima Pharmacokinetics of PC-SOD, a Lecithinized Recombinant Superoxide Dismutase, After Single- and Multiple-Dose Administration to Healthy Japanese and Caucasian Volunteers J. Clin. Pharmacol., February 1, 2008; 48(2): 184 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Schentag, G. Hill, T. Chu, and C. R. Rayner Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects J. Clin. Pharmacol., June 1, 2007; 47(6): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kastrissios, S. Rohatagi, J. Moberly, K. Truitt, Y. Gao, R. Wada, M. Takahashi, K. Kawabata, and D. Salazar Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor. J. Clin. Pharmacol., May 1, 2006; 46(5): 537 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaedigk, L. D. Bradford, S. W. Alander, and J. S. Leeder CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS Drug Metab. Dispos., April 1, 2006; 34(4): 563 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ogino, J. Kido, M. Bando, N. Hayashi, C. Wada, T. Nagata, F. Nishimura, Y. Soga, S. Takashiba, T. Kubota, et al. {alpha}2 Integrin +807 Polymorphism in Drug-induced Gingival Overgrowth J. Dent. Res., December 1, 2005; 84(12): 1183 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Autar, M. Boffito, E. Hassink, F. W. N. M. Wit, J. Ananworanich, U. Siangphoe, A. Pozniak, D. A. Cooper, P. Phanuphak, J. M. A. Lange, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients J. Antimicrob. Chemother., November 1, 2005; 56(5): 908 - 913. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
